Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. We provide leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocate for policies that support their timely approval, reimbursement, market acceptance and expanded use.
Learn more about biosimilars and their benefits for patients and healthcare systems.
As of December 15, 2021, only biosimilars to Lovenox and Lovenox HP enoxaparin will be reimbursed by the Quebec public drug plan. Patients already being treated with Lovenox have until April 12, 2022, to switch to a biosimilar.
As of December 15, 2021, only biosimilars to Forteo teriparatide will be reimbursed by the Quebec public drug plan. Patients currently being treated with Forteo have until April 12, 2022 to switch to a biosimilar.